Abstract: The present invention relates to a fire sprinkler head that once activated can be shut off via a built-in cutoff valve without requiring the flow of fire retardant in the feeding pipe to be cut off.

Abstract: The field of the invention relates to systems and methods for handling CD, USB media storage, etc. within a secure environment like the FBI, various intelligence agencies, the military, and so forth.

Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.

Abstract: A hand-held food processor having a weighted cylindrical universal handle with a circular triangle shaped base which can accommodate various detachable optional base pieces. The base pieces contemplated include a piercing tenderizer assembly, a coarse plate, as well as a smooth plate.

Abstract: An isolated DNA of SEQ ID NO:1 is provided that encodes the transcription factor BP1, which is believed to be a repressor of the ?-globin gene. A host cell that is transformed with a vector that contains the DNA may be used to produce BP1. Vectors having a controllable promoter operably connected to the BP1 open reading frame may be used to transform ?-globin producing cells of patients with sickle cell anemia, thereby providing a treatment. Because BP1 is overexpressed in leukemia and breast cancer cells, acute myeloid leukemia, acute lymphocytic leukemia, and breast cancer can be screened for and diagnosed by determining whether BP1 is overexpressed in cell samples of patients who may have these conditions. An antisense DNA or RNA to the DNA encoding BP1 may be used as a treatment for acute myeloid leukemia, acute lymphocytic leukemia, and breast cancer.

Abstract: 3,4-Dihydroisoquinoline and isoquinoline compounds of formula I, in which Ar represents a phenyl raidcal of the formulae IIa, IIb or IIc are novel effective PDE7 inhibitors.

Abstract: Benzylaminopyrimidine compounds of a certain general formula I, in which the substituents and symbols are as defined in the description, are suitable for controlling Helicobacter bacteria.

Abstract: Compounds of formula (I), in which M, A1, A2, K1 and K2 have the meanings as indicated in the description are novel active tryptase inhibitors.

Abstract: The present invention provides an ion conducting matrix comprising: (i) 5 to 60% by volume of an inorganic powder having a good aqueous electrolyte absorption capacity; (ii) 5 to 50% by volume of a polymeric binder that is chemically compatible with an aqueous electrolyte; and (iii) 10 to 90% by volume of an aqueous electrolyte, wherein the inorganic powder comprises essentially sub-micron particles. The present invention further provides a membrane being a film made of the matrix of the invention and a composite electrode comprising 10 to 70% by volume of the matrix of the invention.

Abstract: The invention relates to compounds of formula (2) in which R1, R2, R3 and R4 have the meanings indicated in the description, their preparation and their further reaction to give compounds of formula (1), in which A1, A2 and R4 have the meanings indicated in the description. The compounds of the formula (1) are valuable intermediates for the preparation of medicaments.

Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.

Abstract: The substitution of the L-Pro at the 7-position of the peptide hormone bradykinin or other substituted analogs of bradykinin with a D-configuration hydroxyproline ether or thioether converts bradykinin agonists into bradykinin antagonists. The invention further includes the intermediate compounds and additional modifications at other positions within the novel 7-position modified bradykinin antagonists which increase enzyme resistance, antagonist potency, and/or specificity of the new bradykinin antagonists. The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected such as by insect bites.

Abstract: The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.

Abstract: This invention relates generally to the gene, and mutations, that are responsible for the disease hemochromatosis (HH). In particular, the present invention provides for the presence of one or more mutations on the ferroportin 1 (SLC11A3) gene which results in aberrant SLC11A3 mediated iron transport. The invention also relates to methods for diagnostic tools, drugs and therapies developed for the treatment of patients with HH or anemia.

Abstract: A method for obtaining DNA from fish spermatogonia comprises (i) disrupting fish spermatogonium to obtain a milky-white colloid, (ii) adding an alkaline solution of pH 8 to pH 12, containing more than 1 mol of salts, such as monovalent salts, to the milky-white colloid, to separate DNA from protamines, and then (iii) adding ethanol solution to the resultant mixture, effecting a precipitation of DNA.

Abstract: The compounds of formula (I) in which R1, R2, A, B and Ar have the meanings as given in the description are novel effective PDe4 inhibitors

Abstract: Process for treatment of gases which are exhausted through a sinter bed in a sintering plant, wherein a distinction can be made between a cold zone of the sintering plant with relatively low gas temperatures and a hot zone of the sintering plant with substantially higher gas temperatures. The gases from the cold zone of the sintering plant and the gases from the hot zone of the sintering plant are exhausted and treated as separate partial flows.

Abstract: The invention relates to compounds of formula (2) in which R1, R2, R3 and R4 have the meanings indicated in the description, their preparation and their further reaction to give compounds of formula (1), in which A1, A2 and R4 have the meanings indicated in the description. The compounds of the formula (1) are valuable intermediates for the preparation of medicaments.

Abstract: The present invention relates to a transition metal-ligand complex that shows changes in its luminescence lifetime characteristic and/or luminescence intensity as a function of the polarity and/or hydrogen bonding properties of its environment, and a sensor, probe, system and method based on the complex for detecting the presence, amount or concentration of a polar solvent in a medium.

Abstract: Compounds of formula (I) in which the substituents as defined in the description are useful for preventing and treating gastrointestinal disorders.